{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:00:28Z","timestamp":1793638828542,"version":"4.5.1"},"reference-count":112,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.kint.2023.10.035","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T12:35:09Z","timestamp":1703162109000},"page":"473-483","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Complement activation and effector pathways in membranous nephropathy"],"prefix":"10.1016","volume":"105","author":[{"given":"Andreas D.","family":"Kistler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Salant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2023.10.035_bib1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2023.10.035_bib2","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.1248943","article-title":"Complement is activated by IgG hexamers assembled at the cell surface","volume":"343","author":"Diebolder","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.kint.2023.10.035_bib3","first-page":"415","article-title":"Inhibition of complement activation by IgG4 antibodies","volume":"64","author":"van der Zee","year":"1986","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.kint.2023.10.035_bib4","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The alternative complement pathway revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.kint.2023.10.035_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-2776(08)04004-2","article-title":"The amplification loop of the complement pathways","volume":"104","author":"Lachmann","year":"2009","journal-title":"Adv Immunol"},{"key":"10.1016\/j.kint.2023.10.035_bib6","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.2215\/CJN.04800511","article-title":"Differential diagnosis of lupus and primary membranous nephropathies by IgG subclass analysis","volume":"7","author":"Song","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib7","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/ndt\/gfx235","article-title":"Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy","volume":"33","author":"Hayashi","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.10.035_bib8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12882-018-1011-5","article-title":"Clinical implications of pathological features of primary membranous nephropathy","volume":"19","author":"Zhang","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/his.13955","article-title":"Histological grading in primary membranous nephropathy is essential for clinical management and predicts outcome of patients","volume":"75","author":"Stangou","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.kint.2023.10.035_bib10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000183255","article-title":"Demonstration of C3d deposits in membranous nephropathy","volume":"37","author":"Doi","year":"1984","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2023.10.035_bib11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/ndt\/17.1.57","article-title":"C5b-9 and adhesion molecules in human idiopathic membranous nephropathy","volume":"17","author":"Papagianni","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.10.035_bib12","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ekir.2020.11.032","article-title":"Establishing a case for anti-complement therapy in membranous nephropathy","volume":"6","author":"Ayoub","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.10.035_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ekir.2022.10.008","article-title":"C5b-9 glomerular deposits are associated with poor renal survival in membranous nephropathy","volume":"8","author":"Teisseyre","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.10.035_bib14","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ekir.2020.01.018","article-title":"Proteomic analysis of complement proteins in membranous nephropathy","volume":"5","author":"Ravindran","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2023.10.035_bib15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/nep.13676","article-title":"Proteomics of human glomerulonephritis by laser microdissection and liquid chromatography-tandem mass spectrometry","volume":"25","author":"Kawata","year":"2020","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.kint.2023.10.035_bib16","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1681\/ASN.2020081165","article-title":"Protocadherin 7-associated membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/pro.5560060201","article-title":"The internal thioester and the covalent binding properties of the complement proteins C3 and C4","volume":"6","author":"Law","year":"1997","journal-title":"Protein Sci"},{"key":"10.1016\/j.kint.2023.10.035_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1746-1596-7-109","article-title":"The continual presence of C3d but not IgG glomerular capillary deposition in stage I idiopathic membranous nephropathy in patients receiving corticosteroid treatment","volume":"7","author":"Zhang","year":"2012","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.kint.2023.10.035_bib19","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1021\/bi500157z","article-title":"The making of a macromolecular machine: assembly of the membrane attack complex","volume":"53","author":"Bubeck","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.kint.2023.10.035_bib20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/ki.1991.242","article-title":"Elevated urinary excretion of the C5b-9 complex in membranous nephropathy","volume":"40","author":"Schulze","year":"1991","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.10.035_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000186513","article-title":"Urinary excretion of terminal complement complexes in glomerular disease","volume":"59","author":"Kusunoki","year":"1991","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2023.10.035_bib22","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ki.1992.143","article-title":"Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy","volume":"41","author":"Brenchley","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.10.035_bib23","first-page":"397","article-title":"The temporal relationship between urinary C5b-9 and C3dg and clinical parameters in human membranous nephropathy","volume":"8","author":"Coupes","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.10.035_bib24","first-page":"1553","article-title":"Urinary excretion of cytokines and complement SC5b-9 in idiopathic membranous glomerulonephritis","volume":"9","author":"Honkanen","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.10.035_bib25","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/ndt\/12.12.2576","article-title":"Antiproteinuric effect of angiotensin-converting enzyme inhibition and C5b-9 urinary excretion in membranous glomerulonephritis","volume":"12","author":"Praga","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2023.10.035_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1523-1755.2000.00812.x","article-title":"Renal C3 synthesis in idiopathic membranous nephropathy: correlation to urinary C5b-9 excretion","volume":"57","author":"Montinaro","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.10.035_bib27","first-page":"7","article-title":"Clinical correlates of serial urinary membrane attack complex estimates in patients with idiopathic membranous nephropathy","volume":"60","author":"Cattran","year":"2003","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1365-2362.2003.01153.x","article-title":"Urinary excretion of complement C3d in patients with renal diseases","volume":"33","author":"Branten","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.kint.2023.10.035_bib29","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/ki.1995.496","article-title":"Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy","volume":"48","author":"Kon","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.10.035_bib30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12882-019-1509-5","article-title":"Complement activation products in the circulation and urine of primary membranous nephropathy","volume":"20","author":"Zhang","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/jcp.29.7.601","article-title":"Significance of urinary C3 excretion in glomerulonephritis","volume":"29","author":"Cumming","year":"1976","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.kint.2023.10.035_bib32","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1681\/ASN.V114700","article-title":"Complement activation products in the urine from proteinuric patients","volume":"11","author":"Morita","year":"2000","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib33","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1681\/ASN.2021101384","article-title":"Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy","volume":"33","author":"Gao","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib34","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jfma.2018.12.026","article-title":"The relationship of anti-phospholipase A2 receptor antibody and C5a complement with disease activity and short-term outcome in idiopathic membranous nephropathy","volume":"118","author":"Chi","year":"2019","journal-title":"J\u00a0Formos Med Assoc"},{"key":"10.1016\/j.kint.2023.10.035_bib35","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2147\/IJGM.S407073","article-title":"Lectin complement pathway activation is associated with massive proteinuria in PLA2R-positive membranous nephropathy: a retrospective study","volume":"16","author":"Li","year":"2023","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.kint.2023.10.035_bib36","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1038\/s41598-019-42689-7","article-title":"Low serum C3 level, high neutrophil-lymphocyte-ratio, and high platelet-lymphocyte-ratio all predicted poor long-term renal survivals in biopsy-confirmed idiopathic membranous nephropathy","volume":"9","author":"Tsai","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2023.10.035_bib37","doi-asserted-by":"crossref","first-page":"F660","DOI":"10.1152\/ajprenal.00437.2004","article-title":"Experimental membranous nephropathy redux","volume":"289","author":"Cybulsky","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2023.10.035_bib38","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1172\/JCI72270","article-title":"Membranous nephropathy: from models to man","volume":"124","author":"Beck","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2023.10.035_bib39","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI109987","article-title":"A\u00a0new role for complement in experimental membranous nephropathy in rats","volume":"66","author":"Salant","year":"1980","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2023.10.035_bib40","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1084\/jem.188.7.1353","article-title":"Inhibition of complement regulation is key to the pathogenesis of active Heymann nephritis","volume":"188","author":"Schiller","year":"1998","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.kint.2023.10.035_bib41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1681\/ASN.0000000000000068","article-title":"Pathogenicity of human anti-PLA 2 R1 antibodies in minipigs: a pilot study","volume":"34","author":"Reinhard","year":"2023","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib42","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2023.10.035_bib43","doi-asserted-by":"crossref","first-page":"8190","DOI":"10.1038\/s41598-020-64863-y","article-title":"Generation of a conditional transgenic mouse model expressing human phospholipase A2 receptor 1","volume":"10","author":"Jaber","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2023.10.035_bib44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.kint.2022.09.008","article-title":"Podocyte expression of human phospholipase A2 receptor 1 causes immune-mediated membranous nephropathy in mice","volume":"103","author":"Tomas","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.10.035_bib45","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41467-023-36068-0","article-title":"The classical pathway triggers pathogenic complement activation in membranous nephropathy","volume":"14","author":"Seifert","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2023.10.035_bib46","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.mayocp.2020.11.028","article-title":"A\u00a0target antigen-based approach to the classification of membranous nephropathy","volume":"96","author":"Bobart","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.kint.2023.10.035_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.10.035_bib48","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.10.035_bib49","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1681\/ASN.2020101395","article-title":"Serine protease HTRA1 as a novel target antigen in primary membranous nephropathy","volume":"32","author":"Al-Rabadi","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281156","article-title":"Contactin-1 links autoimmune neuropathy and membranous glomerulonephritis","volume":"18","author":"Fehmi","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2023.10.035_bib51","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.3389\/fimmu.2018.03035","article-title":"Antigen-specific IgG subclasses in primary and malignancy-associated membranous nephropathy","volume":"9","author":"von Haxthausen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2023.10.035_bib52","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.10.035_bib53","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib54","article-title":"Anti-PLA2R1 antibodies containing sera induce in\u00a0vitro cytotoxicity mediated by complement activation","volume":"2019","author":"Lateb","year":"2019","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.kint.2023.10.035_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.952235","article-title":"The alternative pathway is necessary and sufficient for complement activation by anti-THSD7A autoantibodies, which are predominantly IgG4 in membranous nephropathy","volume":"13","author":"Manral","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2023.10.035_bib56","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ki.2012.209","article-title":"Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy","volume":"82","author":"Hoxha","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.10.035_bib57","doi-asserted-by":"crossref","first-page":"936","DOI":"10.2169\/internalmedicine.41.936","article-title":"Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy","volume":"41","author":"Kuroki","year":"2002","journal-title":"Intern Med"},{"key":"10.1016\/j.kint.2023.10.035_bib58","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00467-009-1439-8","article-title":"IgG subclasses and complement pathway in segmental and global membranous nephropathy","volume":"25","author":"Segawa","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib59","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/modpathol.2012.237","article-title":"IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression","volume":"26","author":"Huang","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kint.2023.10.035_bib60","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/ki.1997.32","article-title":"IgG subclasses in patients with membranoproliferative glomerulonephritis, membranous nephropathy, and lupus nephritis","volume":"51","author":"Imai","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.10.035_bib61","article-title":"Retrospective study of phospholipase A2 receptor and IgG subclasses in glomerular deposits in Chinese patients with membranous nephropathy","volume":"11","author":"Dong","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2023.10.035_bib62","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/ajcp\/83.4.415","article-title":"Immunohistopathologic evaluation of C1q in 800 renal biopsy specimens","volume":"83","author":"Jennette","year":"1985","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.kint.2023.10.035_bib63","first-page":"370","article-title":"Complement system and C4d expression in cases of membranous nephropathy","volume":"39","author":"Cust\u00f3dio","year":"2017","journal-title":"J\u00a0Bras Nefrol"},{"key":"10.1016\/j.kint.2023.10.035_bib64","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cca.2018.06.050","article-title":"Clinical and prognostic significance of glomerular C1q deposits in primary MN","volume":"485","author":"Zhang","year":"2018","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.kint.2023.10.035_bib65","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2023.10.035_bib66","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1038\/s41467-019-11577-z","article-title":"A\u00a0glomerulus-on-a-chip to recapitulate the human glomerular filtration barrier","volume":"10","author":"Petrosyan","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2023.10.035_bib67","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cellimm.2018.07.009","article-title":"Immunoglobulin G glycosylation in aging and diseases","volume":"333","author":"Gudelj","year":"2018","journal-title":"Cell Immunol"},{"key":"10.1016\/j.kint.2023.10.035_bib68","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.3390\/ijms23094664","article-title":"Definition of IgG subclass-specific glycopatterns in idiopathic membranous nephropathy: aberrant IgG glycoforms in blood","volume":"23","author":"Chinello","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2023.10.035_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1087532","article-title":"Factors affecting IgG4-mediated complement activation","volume":"14","author":"Oskam","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2023.10.035_bib70","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1681\/ASN.2019050538","article-title":"Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy","volume":"31","author":"Burbelo","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib71","doi-asserted-by":"crossref","first-page":"217","DOI":"10.34067\/KID.0005112022","article-title":"Prediagnostic appearance of thrombospondin type-1 domain 7A autoantibodies in membranous nephropathy","volume":"4","author":"Burbelo","year":"2023","journal-title":"Kidney360"},{"key":"10.1016\/j.kint.2023.10.035_bib72","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrrheum.2017.146","article-title":"Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?","volume":"13","author":"Seeling","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.kint.2023.10.035_bib73","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1681\/ASN.2015101155","article-title":"Phospholipase A2 receptor-related membranous nephropathy and mannan-binding lectin deficiency","volume":"27","author":"Bally","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib74","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.10.035_bib75","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(04)17142-0","article-title":"Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies","volume":"364","author":"Debiec","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2023.10.035_bib76","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ki.2014.381","article-title":"Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies","volume":"87","author":"Vivarelli","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.10.035_bib77","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2014.367","article-title":"Lessons from a rare disease: IgG subclass and disease severity in alloimmune antenatal membranous nephropathy","volume":"87","author":"Beck","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.10.035_bib78","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1128\/iai.55.1.206-210.1987","article-title":"Formation of transmural complement pores in serum-sensitive Escherichia coli","volume":"55","author":"Bhakdi","year":"1987","journal-title":"Infect Immun"},{"key":"10.1016\/j.kint.2023.10.035_bib79","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1073\/pnas.80.12.3816","article-title":"Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics","volume":"80","author":"Koski","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2023.10.035_bib80","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1042\/CS20020362","article-title":"Beyond lysis: how complement influences cell fate","volume":"104","author":"Cole","year":"2003","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.kint.2023.10.035_bib81","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1172\/JCI112408","article-title":"Complement-induced glomerular epithelial cell injury: role of the membrane attack complex in rat membranous nephropathy","volume":"77","author":"Cybulsky","year":"1986","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2023.10.035_bib82","first-page":"185","article-title":"Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats","volume":"135","author":"Baker","year":"1989","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2023.10.035_bib83","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1172\/JCI111159","article-title":"Role of the terminal complement pathway in experimental membranous nephropathy in the rabbit","volume":"72","author":"Groggel","year":"1983","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2023.10.035_bib84","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4049\/jimmunol.137.5.1511","article-title":"The membrane attack complex in complement-mediated glomerular epithelial cell injury: formation and stability of C5b-9 and C5b-7 in rat membranous nephropathy","volume":"137","author":"Cybulsky","year":"1986","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2023.10.035_bib85","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.4049\/jimmunol.173.6.4190","article-title":"Renal expression of the C3a receptor and functional responses of primary human proximal tubular epithelial cells","volume":"173","author":"Braun","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2023.10.035_bib86","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s10875-013-9970-6","article-title":"C3a, C5a renal expression and their receptors are correlated to severity of IgA nephropathy","volume":"34","author":"Liu","year":"2014","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.kint.2023.10.035_bib87","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/ki.1995.224","article-title":"Active Heymann nephritis in complement component C6 deficient rats","volume":"47","author":"Leenaerts","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.10.035_bib88","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4049\/jimmunol.179.1.172","article-title":"Induction of passive Heymann nephritis in complement component 6-deficient PVG rats","volume":"179","author":"Spicer","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2023.10.035_bib89","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.semnephrol.2013.08.009","article-title":"Complement-mediated cellular injury","volume":"33","author":"Takano","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib90","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1046\/j.1523-1755.2003.00305.x","article-title":"Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy","volume":"64","author":"Saran","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.10.035_bib91","first-page":"207","article-title":"Augmented expression of glomerular basement membrane specific type IV collagen isoforms (alpha3-alpha5) in experimental membranous nephropathy","volume":"110","author":"Minto","year":"1998","journal-title":"Proc Assoc Am Physicians"},{"key":"10.1016\/j.kint.2023.10.035_bib92","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1681\/ASN.2004121098","article-title":"Cellular response to injury in membranous nephropathy","volume":"16","author":"Nangaku","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib93","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.10.035_bib94","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41467-020-15383-w","article-title":"The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis","volume":"11","author":"Xie","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2023.10.035_bib95","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMc1511702","article-title":"A\u00a0mechanism for cancer-associated membranous nephropathy","volume":"374","author":"Hoxha","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.10.035_bib96","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/S0140-6736(22)02039-6","article-title":"Bacterial infection possibly causing autoimmunity: Tropheryma whipplei and membranous nephropathy","volume":"400","author":"Wiech","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2023.10.035_bib97","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2215\/CJN.02930322","article-title":"Toxic occupational exposures and membranous nephropathy","volume":"17","author":"Cremoni","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib98","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4S","key":"10.1016\/j.kint.2023.10.035_bib99","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.10.035_bib100","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2215\/CJN.12461117","article-title":"Management of membranous nephropathy in the PLA(2)R era","volume":"13","author":"Bomback","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib101","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM198404123101503","article-title":"Controlled trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"310","author":"Ponticelli","year":"1984","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.10.035_bib102","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A\u00a0randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib103","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/ki.1995.161","article-title":"A\u00a0controlled trial of cyclosporine in patients with progressive membranous nephropathy","volume":"47","author":"Cattran","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2023.10.035_bib104","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.10.035_bib105","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib106","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2023.10.035_bib107","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"suppl 4","key":"10.1016\/j.kint.2023.10.035_bib108","first-page":"S82","article-title":"Complement-targeted therapeutics: an emerging field enabled by academic drug discovery","volume":"98","author":"Lamers","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.kint.2023.10.035_bib109","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2023.10.035_bib110","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood.2021014868","article-title":"Pegcetacoplan for paroxysmal nocturnal hemoglobinuria","volume":"139","author":"Gerber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.kint.2023.10.035_bib111","doi-asserted-by":"crossref","first-page":"e1436","DOI":"10.1002\/cti2.1436","article-title":"The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation","volume":"12","author":"de Boer","year":"2023","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.kint.2023.10.035_bib112","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N\u00a0Engl J Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823008682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253823008682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:06:03Z","timestamp":1758762363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253823008682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0085253823008682"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2023.10.035","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement activation and effector pathways in membranous nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2023.10.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}